Press Release 2022 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sami-Sabinsa to Showcase Innovative Ingredients at Nutraceuticals Europe Summit & Expo (Spain)

Sami-Sabinsa to Highlight Research-supported Ingredients, Showcase New Beverage Concepts at IFIA Japan 2022

Sami-Sabinsa to Showcase Innovative, Clinically Studied Ingredients at VitaFoods Europe

Sami-Sabinsa Participates in Science Event Honoring the 70th Anniversary of Diplomatic Relations Between India and Japan

Sabinsa to Showcase Innovative Hair Care & Skin Care Actives at NYSCC 2022

Sabinsa to Highlight Innovative Ingredients in April at Three Trades Shows: in-cosmetics® global - 2022 in France, SAPHEX - 2022 in South Africa and SupplySide® EAST in USA

About

Certificates

Global Contacts List

Get in Touch